ADXN Addex Therapeutics Ltd Stock Quote

ADXN [NASD]

Healthcare | Biotechnology | Switzerland

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	5.64M	Perf Week	-8.26%
Market Cap	58.45M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	0.26M	Perf Month	-10.29%
Income	-	PEG	-	EPS next Q	-	Inst Own	0.42%	Short Float	1.62%	Perf Quarter	-2.33%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.03	Perf Half Y	12.84%
Book/sh	-	P/B	-	EPS next Y	-	ROA	-	Target Price	-	Perf Year	-
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	6.19 - 37.52	Perf YTD	-22.61%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-72.36%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	67.53%	ATR	0.67
Employees	19	Current Ratio	-	Sales Q/Q	-79.90%	Oper. Margin	-	RSI (14)	40.70	Volatility	7.42% 5.11%
Optionable	No	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.24	Prev Close	10.95
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	124.15K	Price	10.37
Recom	-	SMA20	-10.48%	SMA50	-13.75%	SMA200	-9.55%	Volume	29,399	Change	-5.30%

Mar-04-21 01:00AM	Addex to Present at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire -5.30%
Feb-24-21 04:00AM	Enamine Extend Collaboration With Prominent Swiss Biotech Business Wire
Feb-17-21 01:00AM	Addex Provides Trading Update and Completes 2020 with Strong Cash Position of CHF18.7 million GlobeNewswire
Feb-16-21 01:00AM	Addex GABAB Positive Allosteric Modulator Demonstrates Promise in Alcohol Use Disorder GlobeNewswire
Jan-21-21 01:00AM	Addex ADX71149 Receives IND Approval to Start a Phase 2a Clinical Study in Epilepsy GlobeNewswire +21.79%
Jan-12-21 01:00AM	Addex to Present at the Baader Helvea Swiss Equities Conference GlobeNewswire
Jan-11-21 04:00PM	Addex Successfully Completes $11.5 Million Capital Increase Including Full Exercise of Underwriters Option to Purchase Additional Securities GlobeNewswire
Jan-06-21 09:00PM	Addex Announces Pricing of $10.0 Million Global Offering GlobeNewswire
Dec-14-20 12:22PM	Addex Announces Filing of Registration Statement for Proposed Public Offering of Securities GlobeNewswire
Nov-03-20 01:00AM	Addex Reports Q3 2020 Financial Results and Provides Corporate Update GlobeNewswire
Nov-02-20 01:06AM	ADDEX THERAPEUTICS TO RELEASE Q3 2020 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON NOVEMBER 3rd, 2020 GlobeNewswire
01:00AM	Addex Receives Additional $2.8 million from Indivior and Extends GABAB PAM Research Collaboration GlobeNewswire
Sep-23-20 01:00AM	Addex to Present at the Investora Conference GlobeNewswire -9.28%
Sep-14-20 01:00AM	Addex Therapeutics to Participate at the H.C. Wainwright 22nd Annual Global Investment Conference GlobeNewswire -6.51%
Aug-31-20 01:00AM	Addex Therapeutics to Participate at the Biotechgate Digital Partnering Conference GlobeNewswire
Aug-27-20 01:00AM	Addex and the SIB Swiss Institute of Bioinformatics Receive Innosuisse Grant to Repurpose Potent Dopamine Antagonist Using Computational Modelling GlobeNewswire -17.36%
Aug-12-20 01:00AM	Addex Reports 2020 Half Year Financial Results and Provides Corporate Update GlobeNewswire
Aug-10-20 01:00AM	Addex Therapeutics to Release Half-Year 2020 Financial Results and Host Conference Call on August 12, 2020 GlobeNewswire -30.07%
Aug-06-20 01:00AM	Addex Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2020 GlobeNewswire +8.21%
Jul-20-20 01:00AM	Van Leeuwenhoeck Issues Updated Addex Equity Research Report GlobeNewswire

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. to develop mGluR2PAM compounds for the treatment of human health. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience